Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of huCD19-CAR T Cells in Relapsed/Refractory CD19+ B-Cell ALL
NCT06447987Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), sponsored by City of Hope. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Nov 2024; status: suspended.
02
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06447987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447987.